A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France.
HIV
Men who have sex with men
Monitoring
PrEP
Prevention
Sexually transmitted infections
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
08
12
2021
revised:
07
02
2022
accepted:
22
02
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
MSM are at particular risk of STIs due to sexual behavior and substance use. HIV PrEP use may increase this risk. Our aim was to comparatively assess incident STIs among different at-risk groups-PLWHIV, HIV-negative PrEP and no-PrEP users-seen at our center early after PrEP implementation. Clinical data were retrospectively collected on 636 MSM seen at the Infectious Diseases Department between September 2016 and October 2018. STI incidence rate was assessed among groups for the whole period, as well as separately for each year of the study. Overall STI incidence rate ratio was higher in HIV-neg when compared to PLWHIV. In multivariate analysis, STI risk was significantly higher among HIV-neg no-PrEP users compared to PLWHIV, while not different between PLWHIV and PrEP users.STI incidence globally increased during the first 2 years after PrEP approval among PLWHIV and no-PrEP users, stated by odds ratio (OR = 1.77 [1.23-2.55], p = 0.0020 and OR = 2.29 [0.91-5.73], p = 0.0774 respectively) while it remained rather stable for HIV-neg PrEP users (OR = 1.19 [0.60-2.38], p = 0.6181). The HIV-neg no-PrEP group remained at higher risk of STI than PLWHIV and PrEP users during the two periods. These results suggest that a proactive approach of an efficient follow-up of MSM participants since PrEP approval may have prevented an increase of the incidence of STIs among PrEP users.
Sections du résumé
BACKGROUND
BACKGROUND
MSM are at particular risk of STIs due to sexual behavior and substance use. HIV PrEP use may increase this risk.
DESIGN
METHODS
Our aim was to comparatively assess incident STIs among different at-risk groups-PLWHIV, HIV-negative PrEP and no-PrEP users-seen at our center early after PrEP implementation.
METHODS
METHODS
Clinical data were retrospectively collected on 636 MSM seen at the Infectious Diseases Department between September 2016 and October 2018. STI incidence rate was assessed among groups for the whole period, as well as separately for each year of the study.
RESULTS
RESULTS
Overall STI incidence rate ratio was higher in HIV-neg when compared to PLWHIV. In multivariate analysis, STI risk was significantly higher among HIV-neg no-PrEP users compared to PLWHIV, while not different between PLWHIV and PrEP users.STI incidence globally increased during the first 2 years after PrEP approval among PLWHIV and no-PrEP users, stated by odds ratio (OR = 1.77 [1.23-2.55], p = 0.0020 and OR = 2.29 [0.91-5.73], p = 0.0774 respectively) while it remained rather stable for HIV-neg PrEP users (OR = 1.19 [0.60-2.38], p = 0.6181). The HIV-neg no-PrEP group remained at higher risk of STI than PLWHIV and PrEP users during the two periods.
CONCLUSION
CONCLUSIONS
These results suggest that a proactive approach of an efficient follow-up of MSM participants since PrEP approval may have prevented an increase of the incidence of STIs among PrEP users.
Identifiants
pubmed: 35251684
doi: 10.1016/j.jve.2022.100065
pii: S2055-6640(22)00003-6
pmc: PMC8891709
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100065Informations de copyright
© 2022 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Euro Surveill. 2019 Mar;24(10):
pubmed: 30862336
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
J Clin Med. 2014 Dec 12;3(4):1386-91
pubmed: 26237608
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):358-364
pubmed: 29210834
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
Lancet Infect Dis. 2018 Jul;18(7):758-768
pubmed: 29776807
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
AIDS. 2018 Jul 17;32(11):1527-1532
pubmed: 29762169
JAMA. 2019 Apr 9;321(14):1380-1390
pubmed: 30964528
HIV Med. 2018 Apr;19(4):261-270
pubmed: 29368440
Sex Transm Infect. 2018 Nov;94(7):494-501
pubmed: 29700052
Sex Health. 2017 Feb;14(1):18-27
pubmed: 27585033
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29
pubmed: 27632233
J Clin Nurs. 2018 Sep;27(17-18):3254-3265
pubmed: 28771856
Sex Transm Infect. 2018 Sep;94(6):406-410
pubmed: 29567802
AIDS Res Ther. 2016 Jan 19;13:5
pubmed: 26793265
Sex Transm Dis. 2018 Sep;45(9):632-635
pubmed: 29509566
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
Sex Transm Infect. 2016 Aug;92(5):365-7
pubmed: 26601852
AIDS. 2018 Feb 20;32(4):523-530
pubmed: 29239887
BMC Infect Dis. 2017 Sep 11;17(1):617
pubmed: 28893203
Lancet Infect Dis. 2019 Jan;19(1):4-6
pubmed: 30409682
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):e9-e13
pubmed: 30334877
Clin Infect Dis. 2016 Dec 1;63(11):1495-1504
pubmed: 27558571
AIDS. 2017 Jul 31;31(12):1709-1714
pubmed: 28700394